December 21, 2020 08:20 AM EST
R&D

Fol­low­ing a quick ap­proval in AML, Astel­las' Xospa­ta flops in chemo com­bo for front­line pa­tients

Nicole DeFeudis

Editor

Two years af­ter land­ing a fast OK in acute myeloid leukemia, Astel­las Phar­ma’s FLT3 in­hibitor Xospa­ta flunked a Phase III tri­al as­sess­ing its abil­i­ty to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times